PHARMACOLOGY & THERAPEUTICS

Executive Editors
W. C. Bowman, A. M. Breckenridge, A. C. Sartorelli.

CHEMOTHERAPY

CLINICAL PHARMACOLOGY & THERAPEUTICS

TOXICOLOGY

OL.
26
984

METABOLIC INHIBITORS

GENERAL & SYSTEMATIC PHARMACOLOGY

Volume contents, Author index
and Subject index to
Volume 26

PERGAMON PRESS OXFORD · NEW YORK

PHARMACOLOGY & THERAPEUTICS

Chemotherapy, Toxicology and Metabolic Inhibitors

Executive Editor: A. C. Sartorelli

Yale University School of Medicine, Department of Pharmacology, 333 Cedar Street, New Haven, Connecticut 06510, USA

Associate Editor: John S. Lazo

Managing Editor: Barbara Z. Renkin, Ph.D.

General and Systematic Pharmacology

Executive Editor: W. C. Bowman

University of Strathclyde, Department of Physiology & Pharmacology, Royal College, 204 George Street, Glasgow G1 1XW, Scotland

Clinical Pharmacology and Therapeutics

Executive Editor: A. M. Breckenridge

University of Liverpool, Department of Pharmacology & Therapeutics, P.O. Box 147, Liverpool L69 3BX, England

Editorial Board

G. E. Adams—*Sutton, Surrey, England*
S. Agoston—*Groningen, Netherlands*
Joseph R. Bertino—*New Haven, Connecticut*
Ernest Bueding—*Baltimore, Maryland*
B. A. Callingham—*Cambridge, England*
Donald S. Coffey—*Baltimore, Maryland*
William A. Creasey—*Philadelphia, Pennsylvania*
P. F. D'Arcy—*Belfast, N. Ireland*
M. A. Denborough—*Canberra, Australia*
Robert L. Dixon—*Washington DC*
Jürgen Drews—*Wien, Austria*
W. F. Dryden—*Edmonton, Alberta, Canada*
B. L. Furman—*Glasgow, Scotland*
George A. Galegov—*Moscow, USSR*
C. F. George—*Southampton, England*
Evgeny Golovinsky—*Sofia, Bulgaria*
Robert E. Handschumacher—*New Haven, Connecticut*
Peter Langen—*Berlin, GDR*
Åke Liljestrand—*Stockholm, Sweden*
Jerry Mitchell—*Houston, Texas*
A. Nies—*Denver, Colorado*
E. E. Ohnhaus—*Essen, German Federal Republic*
M. L'E. Orme—*Liverpool, England*
J. Gy Papp—*Szeged, Hungary*
Robert E. Parks, Jr.—*Providence, Rhode Island*
Sidney Pestka—*Nutley, New Jersey*
William H. Prusoff—*New Haven, Connecticut*
J. L. Reid—*Glasgow, Scotland*
A. Richens—*Cardiff, Wales*
D. S. Savage—*Glasgow, Scotland*
D. G. Shand—*Durham, North Carolina*
David Shugar—*Warsaw, Poland*
F. Sjöqvist—*Huddinge, Sweden*
Jan Škoda—*Prague, Czechoslovakia*
A. Stafford—*Glasgow, Scotland*
Donald J. Tipper—*Worcester, Massachusetts*
E. S. Vesell—*Hershey, Pennsylvania*
George Weber—*Indianapolis, Indiana*
Gerhard Zbinden—*Zürich, Switzerland*

Library Annual Subscription Rates—published in 4 volumes per annum of 3 issues each.
Annual Subscription, 1986, U.S. $800.00 including postage and insurance, 2 years, 1986/87, U.S. $1520.00.
Specially Reduced Rates to Individuals: Any individual whose institution takes out a library subscription may purchase a second or additional subscription for personal use at a much reduced rate of $350.00 annually. Subscribers to the Journal may claim a 20% discount off Encyclopedia volumes.

Subscription enquiries from customers in North America should be sent to Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523, USA, and for the remainder of the world to Pergamon Press Ltd, Headington Hill Hall, Oxford OX3 0BW, England.

At the end of the year, the Subscriber will receive, free, both the annual subject index and an attractive and durable magazine binder, especially designed for *Pharmacology & Therapeutics*.

Copyright © 1985 Pergamon Press Ltd.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organisations which do not permit such assignment. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproduction, microform or any other reproduction of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical photocopying recording or otherwise, without permission in writing from the copyright holder.

U.S. COPYRIGHT LAW APPLICABLE TO USERS IN THE U.S.A.

The Item-Fee Code for this publication indicates that authorization to photocopy items for internal or personal use is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance of $0.50 per page is paid directly to the Copyright Clearance Center Inc., 21 Congress Street, Salem, MA 01970. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt please contact your nearest Pergamon Office.

The Item-Fee Code for this publication is: 0163-7258/84 $0.00 + 0.50

Microform Subscriptions and Back Issues

Back issues of all previously published volumes are available in the regular editions and on microfilm and microfiche. Current subscriptions are available on microfiche simultaneously with the paper edition and on microfilm on completion of the annual index at the end of the subscription year.

Publishing and Advertising Offices

Pergamon Press Ltd.
Headington Hill Hall
Oxford OX3 0BW
England

Pergamon Press Inc.
Maxwell House
Fairview Park, Elmsford
New York 10523, U.S.A.

Volume 26, 1984, Numbers 1–3

CONTENTS

Number 1 PAGE

Synthesis and antiviral properties of 5-vinylpyrimidine nucleoside analogs: *E. De Clercq and R. T. Walker* 1
Transformation by feline retroviruses: *C. J. Sherr* 45
Cellular transformation by adenoviruses: *S. J. Flint* 59
Tumor promotors and cell transformation: *L. Diamond* 89

Number 2

Temperature regulation and anesthesia: *H. M. Chinyanga* 147
Scope of DNA cloning and chemical methods in development of chemotherapeutic agents: *S. A. Narang, R. Brousseau and F. Georges* 163
Nature and properties of mammalian ribonucleoside diphosphate reductase: *L. M. Nutter and Y.-C. Cheng* 191
Age related changes influencing the effects of drugs and other xenobiotics on sensorineural hearing: *R. E. Brummett and R. T. Jackson* 209
Histamine H_2-receptor antagonists and gastric acid secretion: *R. E. Pounder* 221
The mechanism of cell transformation by SV40 and Polyoma virus: *C. Basilico* 235

Number 3

Drugs and other xenobiotics as teratogens: *H. Tuchmann-Duplessis* 273
Drug-related heatstroke: *W. G. Clark and J. M. Lipton* 345
Capsaicin and central control of thermoregulation: *T. Hori* 389
Opiomelanocortins and behavioral adaptation: *B. Bohus* 417

OL.
26
984

AUTHOR INDEX

Basilico, C. 235
Bohus, B. 417
Brousseau, R. 163
Brummett, R. E. 209

Cheng, Y. -C. 191
Chinyanga, H. M. 147
Clark, W. G. 345

De Clercq, E. 1
Diamond, L. 89

Flint, S. J. 59

Georges, F. 163

Hori, T. 389

Jackson, R. T. 209

Lipton, J. M. 345

Narang, S. A. 163
Nutter, L. M. 191

Pounder, R. E. 221

Sherr, C. J. 45

Tuchmann-Duplessis, H. 273

Walker, R. T. 1

SUBJECT INDEX

Actinomycin D, retinal teratology 314, 315
Active avoidance performance
  haloperidol 422
  morphine and naloxone 425
  opiocortin 422, 425
Adenovirus
  cellular transformation 59–81
  EIA and EIB regions 63–7
    functions, EIA 68–72
    functions, EIB 72–6
    product role in transformation 67–76
    products 64–6
  EIA polypeptide properties 79, 80
  EIB 19kd protein properties 80, 81
  EIB 54kd protein properties 80
  transforming genes 59–63
    identification methods 60
  tumorigenicity 76–8
Adverse drug reactions, histamine H_2-antagonists 229–30
Age and drug effects on hearing 209–17
Alcohol teratogenicity 307
Amnesia, pentylene-tetrazol; opiocortin effects 433
Amphetamines and heatstroke 367–9
Anesthesia
  circadian rhythms 158
  hypothermia 157, 158
  and temperature regulation 153–8
  teratogenicity 308
Antagonists, histamine H_2- 221–30
Antibiotics and teratogenicity 319, 320
Anticholinergic drugs
  and heat stroke 356–8
  intoxication 366, 367
Anticoagulants and teratogenicity 311–13
Antidepressants and heatstroke 369–71
Antiemetics and teratogenicity 308–10
Antiprotozoal drugs and teratogenicity 321
Antitumor drugs and teratogenicity 313–19
  alkaloids 313, 314
  alkylating 313
  antibiotics 314
  antimetabolites 314–17
  antimitotic 313
Antiviral compounds, synthesis 1–37
Aspirin, teratogenicity 310, 311

Barbiturates, teratogenicity 299
Behavior
  adaptive
    opiomelanocortins 419–37
    terminology 417–19
  cognitive
    hypophysectomy and replacement 442
    opiocortins 435–7
    psychoactive drug effects 436
Benzodiazepine and teratogenicity 296, 297
(E)-5-(2-Bromovinyl)2′-deoxyuridine 1
  antiviral selectivity 22, 23
  clinical conditions 32
  experimental herpes virus infections 31
  HSV-1 DNA substitution 29
  sister chromatid exchange 36
  virus resistance 34, 35
Burimamide and H_2-antagonism 223
Butyrophenones and teratogenicity 298

Caffeine and teratogenicity 307
Cancer, oncogene role 181–3
Cannabis and teratogenicity 303, 304
Capsaicin
  body temperature effects 389–92
    EEG and heart rate 390
    hypothalamic responses 391
    rat 390, 391
  cardiovascular effects 392, 393
  chronic neural effects 404–7
    neurochemical 406, 407
  colonic temperature changes 403
  cutaneous thermoreceptors 395, 396
  desensitization 399, 400
    body temperature 400
    febrile response 403, 404
    thermoregulation ability 400–3
  extrahypothalamic thermosensitive neuron effects 398
  heat reinforcement operant behavior 394
  neural structure effects 394–9
  PO/AH heating 402
  PO/AH specificity 407
  PO/AH thermosensitive neurons 396–8
  structure 389
  thermoregulatory effector responses 392
Carbamazepine and teratogenicity 302
Carcinogenesis *see also* tumor promotors
  two-stage models 91–5
Carcinogenic agents, action 89
Chemotherapeutic agents and DNA cloning 163
Chromosome aberrations 101
  aetiology 276
  phorbol diesters 109, 110
Chromosome fragmentation 165, 166
Cimetidine
  clinical applications 226–8
  H_2-antagonism features 224–6
  side-effects 228–30
Clomiphene citrate and teratogenicity 291
Congenital malformations, etiology 276, 277
Copper teratogenicity 284, 285
Corticosteroids and teratogenicity 291
Cyclizine and cataracts 308, 309

Diethylstilbestrol and teratogenicity 290, 291
Differentiation, phorbol diester effects 110–13
Dioxine and teratology 328, 329
DNA cloning
  and chemotherapeutic agent development 163–84

interferons 175, 176
peptide hormones 174, 175
vaccines 176–8
DNA, recombinant
cancer understanding 181–3
chromosome fragmentation 165, 166
gene therapy 183, 184
genetic screening 178–81
methodology 164–8
phases 165
recombinant plasmid isolation 167
target gene synthesis 166
DNA sequence analysis 173
dideoxy 172, 173
DNA synthesis
enzymatic 174
phorbol diesters 108
DNA, synthetic 168–73
deblocking steps 171, 172
gene-machine 171
history 169–71
phosphite method 170, 171
phosphotriester approach 169, 170
strategy 168
Drugs
heatstroke 345–78
ototoxic 209–17 *see also* ototoxicity
teratogens 345–78

Ear *see also* ototoxicity
embryological development 210
Embryo, nutrition 274, 275
β-Endorphin
intracerebroventricular effects 440
passive avoidance response 432, 434, 435

Feline leukemia virus 45
exposure 46, 47
genetic structure 46
-induced disease 47, 48
replication 46
Feline retrovirus
family 45
transformation 45–55
Feline sarcoma virus
growth factors 54
isolation 48, 49
kinase genes 51–4
oncogenes 49
structure and replication 49, 50
transcription regulation 50, 51
transforming genes 54
tyrosine-specific protein kinase oncogene 51

Gastric acid secretion and histamine H_2-receptor antagonists 221–30
Genetic screening 179
autoimmune disease 180
cancer susceptibility 181
DNA recombinant technology 178–81
haemoglobin disorders 179, 180
latent virus 181
Genetic therapy 183, 184
Glucagon glaucoma 312

Haloperidol, active avoidance response 422
Heat illness classification 346, 347
Heatstroke, drug-related 345–78
definitions 350
drug contributions 376
drugs causing 349–75
factors predisposing 347, 348
heat loss impairment 351–8
heat production increase 358–75
Hormones, teratogenicity 286–92
Hyperthermia and fever 346
Hypophysectomy and cognitive behavior 442

Imipramine teratogenicity 304, 305, 306
Insulin teratogenicity 311
Interferons, DNA cloning 175, 176

Learning, opiomelanocortin effects 422–6
Lithium and heatstroke 371, 373
Lithium and teratogenicity 299, 300
LSD teratogenicity 303

Manganese and teratogenicity 285
Meprobamate and teratogenicity 297, 298
6-Mercaptopurine and malformations 316, 317
Mercury, opiocortin effects 427–35
consolidation 427–30
retrieval 430–5
Methyl folic acid, brain malformations 283, 284
Metiamide, H_2-antagonism 223, 224
Models
ribonucleotide reductase regulation 201
transformation by polyoma and SV40 263–5
two-stage transformation 113–21
hamster embryo 116–18
human endometrium 121
mouse C3H/101T/2 cells 113–16
mouse epidermis 118, 119
mouse 3T3 116
mouse submandibular 121
rat trachea epithelium 119–21

Naltrexone and passive avoidance response 433
Narcotics and teratogenicity 302, 303
Neonates, nursing area temperature 150, 151
Neuroleptic malignant syndrome 361–6
age distribution 365
drugs inducing and features 363
Neuroleptics, heat loss and heatstroke 351–6
age effects 355
Nicotine and teratogenicity 305–7

Operating room, environmental temperature 156, 157
Opiomelanocortins
adaptive behavior 417–44
behavioral effects 419–37
formation scheme 420
peptide fragments 418, 419
role in learning, memory and cognitive behavior 440–2
site of action 437–40
Oral contraceptives, teratogenicity 286–9
Ototoxicity, drugs causing 209
elderly 215–17
fetal 211–13
neonatal 213, 214

Oxidative phosphorylation uncouplers
agents and features 360, 361
and heatstroke 358–61

Passive avoidance response
β-endorphins 432, 434, 435
opiocortins 428
and retrieval 432
Peptide hormones and DNA cloning 174, 175
Performance, opiomelanocortin effects 423–6
Pesticides and teratogenicity 327–30
Phenothiazines and teratogenicity 295, 296
Phenytoin and teratogenicity 300–2
Phorbol diesters
and anchorage-dependent 102, 103
binding sites 98, 99
cell aggregation 101
cell culture effects 101–13
cell metabolism 101, 104–8
cell surface effects 100–5
cytoskeleton effects 100, 101
differentiation 102, 110–13
DNA effects 101, 108–10
intercellular communication 103
ligand binding 104
lymphokines 107
ornithine decarboxylase 106, 107
protein phosphorylase 106
sister chromatid exchange 101, 109, 110
small molecule transport 103, 104
structure and tumor promotion 96, 97
tumor virus effects 122–4
Pituitary hormones and teratogenicity 292
Placenta functions 275, 276
Polyoma virus
amplification and excision 249
cell transformation 243–5
early proteins 239–41
host control of transformation 262, 263
integrated
expression 251–4
scheme 252
stability 248, 249
integration model 247
map, DNA 236–8
metabolic effects 241–3
replication–recombination model 250
T-antigens 240, 241
transformation models 263–5
transformed cell lines 254, 255
transformed cell properties 244
viral genome in transformed cells 245–51
viral protein
expression 254
role in transformation 259–62
Prenatal physiology 273, 274
Procarbazine and eye malformations 318

Radiation, teratogenicity 324–6
Ranitidine
clinical applications 226–8
H_2-antagonism 224–6
side-effects 228–30
Receptor, histamine H_2-antagonists and gastric acid 221–300
conventional 222
definition 222
drugs 223–6 *see also* cimetidine, ranitidine
Retention behavior, opiocortin effects 426, 427

Ribonucleoside diphosphate reductase 191–204
activator K_m values 198
de novo and salvage pathways 191
DNA synthesis 202
HeLa cell cycle 192, 193
inhibition, nucleoside triphosphate 199
sequence 200
nomenclature 194
regulation 197–201
model 201
physiological 200
structural components 194–7
molecular weights 195
substrate K_m values 198
virus infected cells 201–4
pathway 204

Salicylate intoxication, age effects 362
Sulfonamides, teratogenicity 320, 321
Suramine
and cleft palate 335
limb necrosis 334
SV40 virus
cell transformation 243–5
early proteins 239–41
integrated genomes
early transcripts 251–3
expression 251–4
late transcripts 253, 254
map of DNA 238, 239
metabolic effects 241–3
T-antigens 240
functional map 257
transformation
host control 262, 263
models 263–5
transformed cell lines 254, 255
properties 244
viral genome in transformed cells 245–51
viral protein expression 254–9
role in transformation 256

Temperature regulation 147–58, 345, 346
age extremes 150–2
anesthesia effects 153–8
breathing circuits 155
general 154, 155
intravenous drugs 153
regional block 155, 156
capsaicin effects 389–410
central organization 407–10
CNS lesion and recovery 409, 410
disease effects 152
heat loss 149, 150
heat production 147–9
age and requirement 148
ideal environment 158
multiple thermostats 408
normal 345, 346
premedication drugs 153
Teratogenic factors
detection 277–81
animal tests 279–81
experimental 278–81
retrospective 277
physical and behavioral effects 280, 281
Teratogenic mechanisms 333
cell kinetics 335, 336
maternal metabolism 334, 335

Teratogens, drugs as 273–337
Teratology, occupational 326–30
heavy metals 326, 327
hypoxia 330
pesticides 327–30
physical factors 330
Teratology, postnatal detection 331–3
Thalidomide teratogenicity 292–5
cataracts 293
CNS malformations 293
structure 294
Thyroid hormones, teratogenicity 291, 292
Tinnitus, drugs causing 210
Trace elements teratogenicity 284–6
Transformation
adenovirus 59–81
feline retrovirus 45–55
host control 262, 263
models 263–5
SV40 and polyoma virus 235–65
tumor promotors 89–126
two-stage models 113–21
viral protein roles 255–62
virus-induced enhancement 122–5
Trichlorophenoxyacetic acid (agent orange), teratology 328–30
Trypan blue teratology 334
Tumor promotors
cell transformation 89–126
mouse skin model 91–4
biochemical effects 93
modifiers 94
tumor promotion 92, 93
oncogene modulation 124, 125
phorbol diester 90 *see also* phorbol diester
structures 96, 97
tumor virus effects 122–4
two-stage carcinogenesis model 91–5
Tumorigenicity, adenovirus 76–8
TWR 1339 teratogenicity 311, 312

Vaccines
DNA cloning 176–8
teratogenicity 321–4
5-Vinylpyrimidine nucleoside analogs 1–37
animal models and therapy 30, 32
antiviral mechanisms 22–30
isopycnic centrifugation 29
sequence in HSV-1 24
steps 26, 27
antiviral spectrum 20, 21
cell function effects 21, 22
chemical reactions 13–15
experimental herpes virus infections 31
human efficacy 31, 32
limitations 33
minimum inhibitory concentration and cell system 18, 19
nucleoside synthesis 12, 13
physical structure 15, 16
pyrimidine base synthesis 10–12
selectivity index 3–9
structure–activity relationships 16–18
structure and side chains 2–9
thymidine kinase affinity 25
varicella zoster activity 19, 20
and virus–drug resistance 33–5
virus effects 3–9
Virus *see also* individual viruses
infection and host metabolism 241–3
Vitamins and teratogenicity 281–4

Xanthines and heatstroke 371, 372

Zinc and teratogenicity 285, 286
Zollinger–Ellison syndrome 227

OL.
26
984